A California 501(c)(3) nonprofit research organization
Not treating illness.
Expanding potential.
Metanoia advances the science of natural psychedelics for personal growth and human flourishing, in healthy adults, not just patients.
Where others ask "how do we treat what's broken?" we ask "how do we unlock what's possible?"
We're a young nonprofit building now, and we need founding donors and volunteers to launch our research and education.
Psychedelics are powerful, mostly illegal, and not risk-free. That is exactly why rigorous research and honest education matter. Read the safety page
Our Approach
A different starting point
Today's psychedelic renaissance focuses almost entirely on treating illness. Metanoia prioritizes the everyday, healthy person, someone not seeking therapy, but aspiring to elevate their well-being, creativity, self-awareness, and potential, through a multidisciplinary research approach integrating genetics, chemistry, neuroscience, cultivation, therapy, and sex- and gender-based differences.
For Practitioners
Work outside supervised programs
Some people guide, sit with or host others in psychedelic work outside licensed programs. We do not audit or judge this work. We gather what research and documented traditions report about it, mark every claim with a source and a reliability level, and publish it free. Anyone who works in this field, or studies it, can read it, and can send us comments on our data element set or corrections to what we report.
Multidisciplinary Research
Six integrated disciplines driving a 360° understanding
Neuroscience
How psychedelics, psilocybin, LSD, ayahuasca, iboga, affect brain activity, neuroplasticity, and cognition, in plain language.
Read moreClose
Classic psychedelics share a starting point at the serotonin 2A receptor. At the scale of the whole brain, the clearest shared finding in recent imaging is more communication between networks that usually keep apart, not the shutdown of a single network.
Plasticity is where the interest lies for healthy adults, and where caution is needed. A growth factor rose inside lab-grown human cells, but it did not change in the blood of healthy adults given LSD. What lasts, and whether it matters for growth, is still open.
Genetics
Whether genetic factors shape how individuals respond to psychedelics, across the whole family, for personal development.
Read moreClose
Two questions: the genetics of the mushroom and the genetics of the person. The mushroom side is further along, and most commercial cultivars turn out to share identical psilocybin genes.
On the person side, we have not identified a human study that links a genetic variant to how strongly someone responds to a classic psychedelic. The enzymes and receptors involved are known, which makes this one of the clearest open questions in the field.
Chemistry
Studying natural sources, mushrooms, cacti, vines, and bark, as whole chemical systems, not single molecules.
Read moreClose
A natural source is a chemical system. Psilocybin comes with relatives such as psilocin, baeocystin and aeruginascin, and every plant in the family has its own alkaloids. Measuring them reliably is harder than it looks.
Whether the whole source acts differently from the pure molecule is open. Preliminary animal work hints at it, human validation is lacking, and the whole mushroom has not been shown to be better. It is different, and not yet properly studied.
Cultivation
How species, growing conditions, and handling shape a mushroom's real chemistry, and why every batch can differ.
Read moreClose
Psilocybin content differs between species, within a species and from batch to batch, and it shifts with how the mushroom is dried and stored. That makes cultivation a research variable, not a hobbyist footnote.
Research that does not record how its material was grown cannot be repeated. This discipline also carries our sustainability commitment: cultivable sources over threatened or wild ones.
Therapeutic Practice
How preparation, support, and integration are studied and reported, across every substance in the family.
Read moreClose
The molecule is only part of the story. Preparation, support during the experience and integration afterwards shape what happens, and researchers are only now learning to describe them precisely enough to compare.
Metanoia studies and documents this practice. We do not provide preparation, support, integration or therapy, and we do not supply any controlled substance.
Gender
How sex and gender shape psychedelic response, one of the least-studied questions in the field.
Read moreClose
Do these substances act differently in women and men, or across hormonal states? Women make up close to half of recent trial participants. The serious representation gap is ethnic.
What is missing is analysis by sex and hormonal state. Sex and gender are recorded as separate fields in the standards we build, and differences are reported wherever they appear, including when there are none.
Research Focus
The Mind Unleashed
The twelve dimensions of human potential our research sets out to understand, and measure.
Reviewed
Creativity
The largest controlled trials find no lasting creativity boost from psychedelics in healthy adults, only a temporary, two-sided shift in thinking style during the acute state.
Reviewed
Problem-Solving
No controlled trial found here shows natural psychedelics improving problem-solving in healthy adults, and several show a decline in convergent thinking during the acute state.
Reviewed
Emotional Resilience
The most consistent controlled finding in healthy adults is a lower amygdala response to negative images during the acute state. No controlled trial has made resilience or emotion regulation its main question, and nobody has followed healthy participants through real setbacks.
Reviewed
Social Connection
No controlled trial in healthy adults has yet reported lasting change in social connection, and the two large uncontrolled surveys lost more than half of their participants before the key follow-up.
Reviewed
Self-Awareness
People say self-exploration is why they use psychedelics, but the direct test, a validated self-awareness measure against placebo in healthy adults, has not been run.
Reviewed
Empathy
A few small placebo-controlled laboratory studies found higher self-rated emotional empathy for a few hours, one psilocybin result was not reproduced, and cognitive empathy did not improve. No controlled measurement beyond the session itself exists in healthy adults.
Reviewed
Well-Being
A single, well-supported high-dose session produces a durable, self-rated sense of meaning, but the standardized instruments alongside it mostly do not move, and repeated microdosing shows no consistent benefit over placebo.
Reviewed
Perception
Acute perceptual effects are the best established effects of the classic psychedelics, while performance on perceptual and timing tasks mostly gets worse during them. No study has followed perception in healthy adults afterward, so lasting change is untested.
Reviewed
Learning & Memory
In rodents, psychedelics change brain structure and speed up fear extinction. In healthy people the best-quantified result is acute, with slower reaction times and worse memory scores in proportion to dose, and no controlled study shows a lasting improvement.
Reviewed
Mindfulness
Evidence that classic psychedelics raise mindfulness in healthy adults is thin and mixed. In the best controlled trials the result is small or absent once a placebo and the surrounding retreat are accounted for.
Reviewed
Nature Connectedness
People who have used psychedelics score higher on nature relatedness, and small uncontrolled studies report rises, but no randomized, placebo-controlled study in healthy adults has tested the question.
Reviewed
Leadership
No controlled study has measured leadership after a psychedelic in healthy adults. The nearest evidence concerns related traits such as openness and flexibility, and none of it was rated by the people a person leads.
Expanding human consciousness, studied rigorously, shared openly.
The Measurement Problem
Twelve dimensions, and we have not identified an agreed way to measure them
Study after study measures growth in healthy adults with instruments built for illness, and we have found few that record what a person was seeking, or whether they found it, months later. Building that missing standard, openly and free to reuse, is the first of Metanoia's research projects, one part of a wider program of research and education.
Why It Matters
A large, unmet, and largely overlooked need
Public Education
We publish what we learn, free to everyone
Research only matters if people can use it. Alongside our guides and education pages, our first full-length open-access title explores psilocybin mushrooms not as one molecule but as a living chemical system: biosynthesis, the entourage of related compounds, dose and variability, cultivation, and the ethics of traditional knowledge. Rigorous for experts, clear for newcomers, and free for both.
How We're Built
The Metanoia model
Today Metanoia is a California 501(c)(3) public charity, and nothing else: it leads research direction, public education, governance, and fundraising. Our long-term plan contemplates a separate for-profit research affiliate, limited in scope to contracted institutional research. That affiliate has not been formed. Any future incentive for whoever leads it, including founder equity, would need independent review, a fair value, and public disclosure. None exists today.
All public education and fundraising benefits the nonprofit mission.
Our Stance
"The psychedelic renaissance is happening with or without proper guidance. Our choice is whether it unfolds safely, scientifically, and equitably, and whether it serves the everyday person seeking to thrive, not only the patient seeking a cure."
Metanoia is built around the science, not around personalities.
Support the Mission
Help us unlock what's possible
Your gift fuels rigorous research and free public education that can help healthy adults thrive. Gifts may be deductible for federal income tax purposes, depending on the donor's own tax position.